Synchronous multiple myeloma and acute myeloid leukaemia: a rare case report


Erakın M., Pehlivan F. S., Atmış Ö., Miskioğlu H. M.

38th European Congress of Pathology, Stockholm, İsveç, 12 - 16 Eylül 2026, cilt.489, sa.1, ss.733, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 489
  • Basıldığı Şehir: Stockholm
  • Basıldığı Ülke: İsveç
  • Sayfa Sayıları: ss.733
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Background & Objectives: Multiple myeloma (MM) and acute myeloid leukaemia (AML) are clonal hematologic malignancies arising from different cell lineages. Their synchronous occurrence is exceptionally rare and represents a major diagnostic and therapeutic challenge, often associated with an adverse prognosis. Methods: A 68-year-old woman with no prior medical history presented with fatigue. Laboratory evaluation revealed leukocytosis, prompting bone marrow examination. The patient's bone marrow biopsies were evaluated histopathologically. Results: The initial biopsy established AML (M1–M2), with neoplastic cells positive for MPO and CD33, and approximately 50% positivity for CD34 and CD117. Notably, a concomitant plasma cell population (~10%), highlighted by CD38 and CD138, raised suspicion for an underlying plasma cell neoplasm. The patient received azacitidine– venetoclax therapy. On day 22, follow-up bone marrow evaluation demonstrated a marked reduction in leukemic blasts, consistent with remission, while the plasma cell population persisted. Light chain analysis confirmed kappa restriction, supporting clonality. After temporary interruption of therapy due to infection, a subsequent bone marrow biopsy revealed re-expansion of leukemic blasts (CD34 ~30%, CD117 ~60%) along with 10–15% neoplastic plasma cells positive for CD38, CD138, and CD56, again showing kappa light chain restriction. These findings confirmed the simultaneous activity of both malignancies. Conclusion: This case highlights the rare coexistence of MM and AML in a single patient and underscores the importance of comprehensive bone marrow evaluation, including careful assessment of plasma cell populations. The absence of standardized treatment guidelines necessitates individualized and multidisciplinary therapeutic approaches. Recognizing this rare entity is crucial, as early identification may influence clinical decision-making and potentially improve patient outcomes.